Browse by Phase
Phase 2 / Phase 3 Clinical Trials
Phase 2/3 combined trials bridge efficacy assessment and large-scale comparison, enrolling larger cohorts while still gathering dose-response data.
Total Trials
122
Recruiting Now
122
Top Conditions in Phase 2 / Phase 3
Gastric Cancer (2) Pancreatic Ductal Adenocarcinoma (2) Breast Cancer (2) Non-Squamous Non-Small Cell Lung Cancer (2) Primary Central Nervous System Lymphoma (2) Multiple Myeloma (2) HCC (2) Heart Failure (2) Acute Myeloid Leukemia (2) Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) (1)
Frequently Asked Questions — Phase 2 / Phase 3 Trials
What distinguishes a Phase 2/3 combined trial?
Phase 2/3 combined trials bridge efficacy assessment and large-scale comparative confirmation in a single expanding protocol. The Phase 2 portion identifies optimal dosing and collects early efficacy signals, while the Phase 3 portion expands enrollment and applies the primary statistical analysis to a larger population. This design reduces time from dose selection to pivotal evidence.
How large are Phase 2/3 combined trials?
Phase 2/3 trials are larger than standalone Phase 2 studies but may be smaller than fully powered Phase 3 trials. Enrollment typically ranges from 200 to 1,000 participants, depending on the condition, endpoint, and statistical requirements. Interim analyses allow sample size adjustment if early results indicate more statistical power is needed.
Who benefits most from Phase 2/3 trial designs?
Phase 2/3 designs particularly benefit patients with serious or rare conditions where standard treatments are inadequate. Because the Phase 2 and Phase 3 portions run as one continuous protocol, patients who enroll in Phase 2 may transition into the Phase 3 portion without interruption—a continuity of care advantage compared to sequential separate studies.
Active Phase 2 / Phase 3 Studies
NCT07005102 Phase 2, Phase 3
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Teli...
Condition
Non-Squamous Non-Small Cell Lung Cancer
Enrollment
854 pts
Location
United States, Australia, Belgium
Sponsor
AbbVie
NCT07454837 Phase 2, Phase 3
Recruiting
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participan...
Condition
Chronic Hepatitis D
Enrollment
120 pts
Location
Austria, Czechia, France
Sponsor
Mirum Pharmaceuticals, Inc.
NCT06933914 Phase 2, Phase 3
Recruiting
Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysm...
Condition
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Enrollment
120 pts
Location
China
Sponsor
Wuhan Createrna Science and Te
NCT04982419 Phase 2, Phase 3
Recruiting
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive H...
Condition
Acute Kidney Injury
Enrollment
240 pts
Location
United States
Sponsor
VA Office of Research and Deve
NCT07399587 Phase 2, Phase 3
Recruiting
Optimizing HFrEF Patients Using BaroStim and CardioMems
Condition
Heart Failure NYHA Class III
Enrollment
15 pts
Location
United States
Sponsor
Northwell Health
NCT06647498 Phase 2, Phase 3
Recruiting
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or...
Condition
Alzheimers Disease
Enrollment
280 pts
Location
United States, Argentina, Australia
Sponsor
Washington University School o
NCT05860465 Phase 2, Phase 3
Recruiting
Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Trea...
Condition
Locally Advanced or Metastatic Breast Cancer
Enrollment
254 pts
Location
China
Sponsor
Shanghai Pharmaceuticals Holdi
NCT02395497 Phase 2, Phase 3
Recruiting
Human Penile Allotransplantation
Condition
Amputation
Enrollment
60 pts
Location
United States
Sponsor
Johns Hopkins University
NCT04256317 Phase 2, Phase 3
Recruiting
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplas...
Condition
Myelodysplastic Syndromes
Enrollment
316 pts
Location
United States, Canada, Czechia
Sponsor
Taiho Oncology, Inc.
NCT06926868 Phase 2, Phase 3
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Prev...
Condition
Breast Neoplasms
Enrollment
500 pts
Location
United States, Argentina, Australia
Sponsor
Bristol-Myers Squibb
NCT06050148 Phase 2, Phase 3
Recruiting
Faecal Microbiota Transplantation as Means of Preventing Recurrent Urinary Tract...
Condition
Recurrent Urinary Tract Infection
Enrollment
100 pts
Location
Finland
Sponsor
Helsinki University Central Ho
NCT07079735 Phase 2, Phase 3
Recruiting
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
Condition
CMV Viremia
Enrollment
150 pts
Location
United States
Sponsor
Columbia University
NCT06965998 Phase 2, Phase 3
Recruiting
A Pilot Trial Comparing Full Dose Rivaroxaban to Prophylactic Dose Rivaroxaban i...
Condition
SVT
Enrollment
50 pts
Location
Canada
Sponsor
Ottawa Hospital Research Insti
NCT05699655 Phase 2, Phase 3
Recruiting
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus ...
Condition
Immunotherapy Gastrict Cancer
Enrollment
130 pts
Location
China
Sponsor
Fujian Cancer Hospital
NCT03720262 Phase 2, Phase 3
Recruiting
Prevention of Hernia After Loop Ileostomy Reversal
Condition
Loop Ileostomy
Enrollment
208 pts
Location
Sweden
Sponsor
Karolinska Institutet
NCT05786768 Phase 2, Phase 3
Recruiting
Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Depend...
Condition
Steroid-Dependent Nephrotic Syndrome
Enrollment
88 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux
NCT06788990 Phase 2, Phase 3
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With...
Condition
Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment
650 pts
Location
United States, Argentina, Australia
Sponsor
Bicara Therapeutics
NCT07462143 Phase 2, Phase 3
Recruiting
A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresect...
Condition
Colorectal (Colon or Rectal) Cancer
Enrollment
80 pts
Location
China
Sponsor
RemeGen Co., Ltd.
NCT05805098 Phase 2, Phase 3
Recruiting
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
Condition
Acute Myeloid Leukemia
Enrollment
60 pts
Location
China
Sponsor
The First Affiliated Hospital
NCT07379047 Phase 2, Phase 3
Recruiting
Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal ...
Condition
GIST - Gastrointestinal Stromal Tumor
Enrollment
255 pts
Location
China, South Korea
Sponsor
Ningbo Newbay Technology Devel
NCT04576143 Phase 2, Phase 3
Recruiting
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemot...
Condition
HER2-negative Breast Cancer
Enrollment
260 pts
Location
China
Sponsor
Second Affiliated Hospital, Sc
NCT01810913 Phase 2, Phase 3
Recruiting
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizum...
Condition
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma
Enrollment
613 pts
Location
United States, Canada, Hong Kong
Sponsor
National Cancer Institute (NCI
Page 5 of 5 — 122 trials total
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology